Görkem Türkkan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Görkem Türkkan has a total of 79 co-authors. Here are the top co-authors by number of shared publications:
- Ali Alkan
Department of Medical Oncology, Mugla Sıtkı Kocman University, Mugla, Turkey
4 shared publications Özgür Tanrıverdi
Department of Medical Oncology, Muğla Sıtkı Koçman University Medical Faculty, Muğla, Turkey
4 shared publicationsEbru Tastekin
2 shared publicationsMurat Caloglu
2 shared publicationsVuslat Yurut Caloglu
2 shared publicationsA Alkan
Department of Medical Oncology, Muğla Sıtkı Koçman University Medical Faculty, Muğla, Turkey
1 shared publication
Latest Publications
- 26 March 2026
- Published by Bulent Evcevit University in Medical Journal of Western Black Sea
- Vol. 10 (1) , 49-59
Clinical and radiological response assessment after whole brain radiotherapy for patients with non-small cell lung cancer with brain metastases
Aim: This study aims to evaluate the response of brain metastases to whole-brain radiotherapy (WBRT) and the role of this treatment in influencing that response.Material and Methods: The study involved eighteen patients who received WBRT for brain metastases either at the time of diagnosis or during the course of their disease. Magnetic resonance imaging (MRI) and neurological examinations were conducted 4 to 6 weeks and 8 to 10 weeks after the completion of WBRT.Results: According to our radiologic assessment, two patients (17%) had a complete response, six patients (50%) had a partial response, and four patients (33%) had stable disease 8-10 weeks after WBRT. The lesion of two patients with solitary brain metastasis vanished, and one lesion of two patients with multiple metastases radiologically disappeared at 8-10 weeks after WBRT. During the initial measurement, the diameter of the biggest lesion was 0.6 to 4.3 cm (average 2.5 cm), 8-10 weeks after whole brain radiotherapy, the corresponding diameter was 0 to 3.5 cm (average 1.6 cm). When the tumor volumes were evaluated, the range was between 78 mm3 and 623 mm3. The volumes at diagnosis and first magnetic resonance imaging after radiotherapy were compared, and a significant response rate was obtained (p=0.008). After WBRT, a decrease in intensity or disappearance of the initial neurological symptoms and signs was seen in all patients.Conclusion: In our study, WBRT provided a neurologic improvement in the patients with brain metastases, and 8-10 weeks after WBRT, a measurable reduction occurred in the size of the lesions in many of them. There is a need for studies with longer follow-ups and more patients focusing on the clinical utility of these findings.
- 26 March 2026
- Published by Bulent Evcevit University in Medical Journal of Western Black Sea
- Vol. 10 (1) , 49-59
Clinical and radiological response assessment after whole brain radiotherapy for patients with non-small cell lung cancer with brain metastases
Aim: This study aims to evaluate the response of brain metastases to whole-brain radiotherapy (WBRT) and the role of this treatment in influencing that response.Material and Methods: The study involved eighteen patients who received WBRT for brain metastases either at the time of diagnosis or during the course of their disease. Magnetic resonance imaging (MRI) and neurological examinations were conducted 4 to 6 weeks and 8 to 10 weeks after the completion of WBRT.Results: According to our radiologic assessment, two patients (17%) had a complete response, six patients (50%) had a partial response, and four patients (33%) had stable disease 8-10 weeks after WBRT. The lesion of two patients with solitary brain metastasis vanished, and one lesion of two patients with multiple metastases radiologically disappeared at 8-10 weeks after WBRT. During the initial measurement, the diameter of the biggest lesion was 0.6 to 4.3 cm (average 2.5 cm), 8-10 weeks after whole brain radiotherapy, the corresponding diameter was 0 to 3.5 cm (average 1.6 cm). When the tumor volumes were evaluated, the range was between 78 mm3 and 623 mm3. The volumes at diagnosis and first magnetic resonance imaging after radiotherapy were compared, and a significant response rate was obtained (p=0.008). After WBRT, a decrease in intensity or disappearance of the initial neurological symptoms and signs was seen in all patients.Conclusion: In our study, WBRT provided a neurologic improvement in the patients with brain metastases, and 8-10 weeks after WBRT, a measurable reduction occurred in the size of the lesions in many of them. There is a need for studies with longer follow-ups and more patients focusing on the clinical utility of these findings.
- Open Access
- 30 December 2022
- Published by Mugla Sitki Kocman University in Muğla Sıtkı Koçman Üniversitesi Tıp Dergisi
- Vol. 9 (3) , 304-308
Squamous Cell Carcinoma of The Skin Mimicking Breast Cancer: A Case Report
Squamous cell carcinoma (SCC) is the second most common skin cancer and it often occurs in sun-exposed areas such as head and neck skin. Invasive SCC located on breast skin is a rare entity and may clinically mimic breast cancer. We report a case of a 39 years old female with a non-eroded, vegetative, growing lesion on the right breast skin, initially mimicking breast cancer both clinically and histopathologically. After surgery with clear margins, adjuvant radiotherapy was administered, by considering the pathological risk factors for recurrence. At 14 months, the patient is disease-free and under regular follow-up. Invasive SCC of the breast skin is a rare entity and may have different etiology/behavior or directly develop de novo when compared to SCCs located on sun-exposed skin. Medical history and physical examination in conjunction with histopathological examination of the biopsy specimen are critical for the accuracy of the diagnosis and the correct treatment decision in patients presenting with a mass invading breast skin.
- 30 December 2022
- Published by Mugla Sitki Kocman University in Muğla Sıtkı Koçman Üniversitesi Tıp Dergisi
- Vol. 9 (3) , 304-308
Open AccessSquamous Cell Carcinoma of The Skin Mimicking Breast Cancer: A Case Report
Squamous cell carcinoma (SCC) is the second most common skin cancer and it often occurs in sun-exposed areas such as head and neck skin. Invasive SCC located on breast skin is a rare entity and may clinically mimic breast cancer. We report a case of a 39 years old female with a non-eroded, vegetative, growing lesion on the right breast skin, initially mimicking breast cancer both clinically and histopathologically. After surgery with clear margins, adjuvant radiotherapy was administered, by considering the pathological risk factors for recurrence. At 14 months, the patient is disease-free and under regular follow-up. Invasive SCC of the breast skin is a rare entity and may have different etiology/behavior or directly develop de novo when compared to SCCs located on sun-exposed skin. Medical history and physical examination in conjunction with histopathological examination of the biopsy specimen are critical for the accuracy of the diagnosis and the correct treatment decision in patients presenting with a mass invading breast skin.
- 14 September 2022
- Published by Galenos Yayinevi in Journal of Urological Surgery
- Vol. 9 (3) , 159-164
Evaluation of Risk Groups for the Prediction of Biochemical Progression in Patients Undergoing Radical Prostatectomy
- 14 September 2022
- Published by Galenos Yayinevi in Journal of Urological Surgery
- Vol. 9 (3) , 159-164
Evaluation of Risk Groups for the Prediction of Biochemical Progression in Patients Undergoing Radical Prostatectomy
- Open Access
- 16 August 2022
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 12, 909402
Clinical utility of a 1.5 T magnetic resonance imaging-guided linear accelerator during conventionally fractionated and hypofractionated prostate cancer radiotherapy
Purpose: To report our initial experience with 1.5 T magnetic resonance imaging (MRI) linear accelerator (LINAC) in prostate cancer radiotherapy in terms of its use in a radiation oncology clinic.Methods: The medical records of 14 prostate cancer patients treated with MRI-guided radiotherapy were retrospectively evaluated. The fraction time, adapt-to-position (ATP):adapt-to-shape (ATS) usage rate, machine-associated treatment interruption rate, median gamma pass rate, the percentage of planning target volume receiving at least 95% of the prescription dose coverage value of each ATS fraction, the effect of the learning curve on the fraction time and radiation-related acute gastrointestinal and genitourinary toxicities were evaluated.Results: Fourteen patients have completed their treatment receiving a total of 375 fractions. Six patients (42%) were treated with the moderately hypofractionated regimen, five patients (36%) with conventionally fractionated, and three patients (22%) with the ultra-hypofractionated radiotherapy regimens. The ATP : ATS usage ratio was 3:372. The median fraction time was 46 min (range, 24-81 min). For the 3%/3 mm criterion, median gamma pass rate was 99.4% (range, 94.6–100%). Machine-related treatment interruptions were observed in 11 (2.9%) of 375 fractions, but this interruption rate decreased from 4.1% to 0.8%, after an upgrade. Three patients (22%) had gastrointestinal and five patients (36%) had genitourinary toxicity. No ≥grade 3 toxicity was observed.Conclusion: 1.5 T MRI-LINAC device could be used as a conventional LINAC device, when the conditions of the radiotherapy center are appropriate. MRI-guided prostate radiotherapy is safe and feasible, and high-quality studies with a larger number of patients and long-term results are needed to better evaluate this new technology.
- 16 August 2022
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 12, 909402
Open AccessClinical utility of a 1.5 T magnetic resonance imaging-guided linear accelerator during conventionally fractionated and hypofractionated prostate cancer radiotherapy
Purpose: To report our initial experience with 1.5 T magnetic resonance imaging (MRI) linear accelerator (LINAC) in prostate cancer radiotherapy in terms of its use in a radiation oncology clinic.Methods: The medical records of 14 prostate cancer patients treated with MRI-guided radiotherapy were retrospectively evaluated. The fraction time, adapt-to-position (ATP):adapt-to-shape (ATS) usage rate, machine-associated treatment interruption rate, median gamma pass rate, the percentage of planning target volume receiving at least 95% of the prescription dose coverage value of each ATS fraction, the effect of the learning curve on the fraction time and radiation-related acute gastrointestinal and genitourinary toxicities were evaluated.Results: Fourteen patients have completed their treatment receiving a total of 375 fractions. Six patients (42%) were treated with the moderately hypofractionated regimen, five patients (36%) with conventionally fractionated, and three patients (22%) with the ultra-hypofractionated radiotherapy regimens. The ATP : ATS usage ratio was 3:372. The median fraction time was 46 min (range, 24-81 min). For the 3%/3 mm criterion, median gamma pass rate was 99.4% (range, 94.6–100%). Machine-related treatment interruptions were observed in 11 (2.9%) of 375 fractions, but this interruption rate decreased from 4.1% to 0.8%, after an upgrade. Three patients (22%) had gastrointestinal and five patients (36%) had genitourinary toxicity. No ≥grade 3 toxicity was observed.Conclusion: 1.5 T MRI-LINAC device could be used as a conventional LINAC device, when the conditions of the radiotherapy center are appropriate. MRI-guided prostate radiotherapy is safe and feasible, and high-quality studies with a larger number of patients and long-term results are needed to better evaluate this new technology.
- 1 April 2022
- Published by Medknow in Nigerian Journal of Clinical Practice
- Vol. 25 (4) , 448-453
Preoperative Radiotherapy for Rectal Cancer
Background and Aims: Preoperative long-course radio-chemotherapy (LC-RCHT) or preoperative short-course radiotherapy (SC-RT) are widely used in the treatment of locally advanced rectal cancer (LARC). This study aimed to evaluate the 100 most-cited research articles focused on preoperative radiotherapy for rectal cancer to reveal existing academic trends and the direction of therapeutic research. Materials and Methods: This was a retrospective study based on publicly accessible data. The Web of Science database was used to identify the 100 most-cited articles. Results: The median values for total citation and average citation per year (CPY) were 240.50 (range, 150–3787) and 17.32 (5.03–222.76), respectively. Randomized (median: 24.88 vs 13.32, P = 0.001) and funded (median: 27.33 vs 14.73, P = 0.002) studies had more CPY than those with opposite characteristics. No significant difference was found between studies using SC-RT and LC-RCHT, in terms of average CPY (median: 15.27 for SC-RT vs 18.36 for LC-RCHT, P = 0.303). In terms of the primary aim of the investigation, studies investigating non-operative treatment strategies had higher CPY than those investigating other subcategories (p = 0.029). Conclusion: Randomized studies, funded studies, and studies investigating non-operative treatment were associated with more CPY. There remains equal interest in preoperative SC-RT and LC-RCHT for rectal cancer.
- 1 April 2022
- Published by Medknow in Nigerian Journal of Clinical Practice
- Vol. 25 (4) , 448-453
Preoperative Radiotherapy for Rectal Cancer
Background and Aims: Preoperative long-course radio-chemotherapy (LC-RCHT) or preoperative short-course radiotherapy (SC-RT) are widely used in the treatment of locally advanced rectal cancer (LARC). This study aimed to evaluate the 100 most-cited research articles focused on preoperative radiotherapy for rectal cancer to reveal existing academic trends and the direction of therapeutic research. Materials and Methods: This was a retrospective study based on publicly accessible data. The Web of Science database was used to identify the 100 most-cited articles. Results: The median values for total citation and average citation per year (CPY) were 240.50 (range, 150–3787) and 17.32 (5.03–222.76), respectively. Randomized (median: 24.88 vs 13.32, P = 0.001) and funded (median: 27.33 vs 14.73, P = 0.002) studies had more CPY than those with opposite characteristics. No significant difference was found between studies using SC-RT and LC-RCHT, in terms of average CPY (median: 15.27 for SC-RT vs 18.36 for LC-RCHT, P = 0.303). In terms of the primary aim of the investigation, studies investigating non-operative treatment strategies had higher CPY than those investigating other subcategories (p = 0.029). Conclusion: Randomized studies, funded studies, and studies investigating non-operative treatment were associated with more CPY. There remains equal interest in preoperative SC-RT and LC-RCHT for rectal cancer.
- 1 February 2021
- Published by Elsevier in Radiotherapy and Oncology
- Vol. 155, 269-277
Idiopathic pulmonary fibrosis: Current knowledge, future perspectives and its importance in radiation oncology
- 1 February 2021
- Published by Elsevier in Radiotherapy and Oncology
- Vol. 155, 269-277
Idiopathic pulmonary fibrosis: Current knowledge, future perspectives and its importance in radiation oncology
- 1 January 2021
- Published by LookUs Bilisim A.S. in Turkish Journal of Oncology
- Vol. 36 (1) , 42-51
Active Surveillance Perspectives of Radiation Oncologists, Medical Oncologists and Urologists in the Treatment of Prostate Cancer
- 1 January 2021
- Published by LookUs Bilisim A.S. in Turkish Journal of Oncology
- Vol. 36 (1) , 42-51
Active Surveillance Perspectives of Radiation Oncologists, Medical Oncologists and Urologists in the Treatment of Prostate Cancer
- 22 February 2020
- Published by Springer Nature in Indian Journal of Hematology and Blood Transfusion
- Vol. 36 (4) , 640-645
Demographical and Clinical Features of Marginal Zone Lymphomas: A Retrospective Study of Turkish Oncology Group (TOG)
Marginal zone lymphomas (MZLs) are rare and indolent subtypes of non-Hodgkin lymphomas, and their clinical behaviours are heterogeneous. The aim of this study was to evaluate the clinical and prognostic characteristics of MZL. In this multicentre retrospective study, we analyzed demographical, clinical and prognostic features of 64 MZL patients. The median age was 54.0 and 78.1% of the patients had extra-nodal disease at presentation. Most of the patients were treated with chemotherapy. The 5 years and 10 years overall survival (OS) rates were 74.5% and 62.1%, respectively. The analysis of factors associated with OS showed that ECOG performance score was an important prognostic factor, with 133.0 months (95% CI 49.3–216.5) versus 18.0 months (95% CI 12.1–23.7) for ECOG 0–1 and 2–3, respectively (p = 0.011). Prognosis of MZL is favorable and ECOG performance score was found associated with OS. Further detailed studies with large patient numbers are needed to clarify the clinical features and treatment management of MZLs.
- 22 February 2020
- Published by Springer Nature in Indian Journal of Hematology and Blood Transfusion
- Vol. 36 (4) , 640-645
Demographical and Clinical Features of Marginal Zone Lymphomas: A Retrospective Study of Turkish Oncology Group (TOG)
Marginal zone lymphomas (MZLs) are rare and indolent subtypes of non-Hodgkin lymphomas, and their clinical behaviours are heterogeneous. The aim of this study was to evaluate the clinical and prognostic characteristics of MZL. In this multicentre retrospective study, we analyzed demographical, clinical and prognostic features of 64 MZL patients. The median age was 54.0 and 78.1% of the patients had extra-nodal disease at presentation. Most of the patients were treated with chemotherapy. The 5 years and 10 years overall survival (OS) rates were 74.5% and 62.1%, respectively. The analysis of factors associated with OS showed that ECOG performance score was an important prognostic factor, with 133.0 months (95% CI 49.3–216.5) versus 18.0 months (95% CI 12.1–23.7) for ECOG 0–1 and 2–3, respectively (p = 0.011). Prognosis of MZL is favorable and ECOG performance score was found associated with OS. Further detailed studies with large patient numbers are needed to clarify the clinical features and treatment management of MZLs.
- 6 February 2020
- Published by SAGE Publications in Journal of Oncology Pharmacy Practice
- Vol. 26 (6) , 1495-1498
Management of a glottic squamous cell carcinoma with cutaneous metastasis
Introduction: Oral cavity malignancies constitute 30% of head and neck cancers. The most common distant metastatic sites of glottic carcinoma are usually lung, liver and bone. Although the cutaneous metastasis of head and cancers have been reported with an incidence of 0.7–2.4%, skin metastasis of glottic carcinoma is extremely rare. Case report: A 69-year-old male patient was admitted to the emergency department with hemoptysis, dyspnea, weakness in lower extremities and difficulty in swallowing. There were subcutaneous lesions with a diameter of 2–5 cm in the scalp, posterior chest wall, nose and abdomen. In addition, there was an ulcerating, painful mass on the right lateral part of the tongue. The biopsy of lesions on tongue and skin revealed a glottic squamous cell carcinoma with cutaneous metastasis. Management and outcome: The patient was treated with cisplatin 50 mg/m2 on day 1, cetuximab 500 mg/m2 on day 1 and 5-fluorouracil 1000 mg/m2 daily on days 1 and 2, repeated every two weeks. After the first cycle of chemotherapy, the lesions on the skin regressed and dysphagia improved. Discussion: There are limited data about the incidence, diagnostic measures and treatment modalities of glottic cancer with cutaneous metastasis. Our case could provide an important experience to literature by its atypical presentation and treatment-sensitive nature.
- 6 February 2020
- Published by SAGE Publications in Journal of Oncology Pharmacy Practice
- Vol. 26 (6) , 1495-1498
Management of a glottic squamous cell carcinoma with cutaneous metastasis
Introduction: Oral cavity malignancies constitute 30% of head and neck cancers. The most common distant metastatic sites of glottic carcinoma are usually lung, liver and bone. Although the cutaneous metastasis of head and cancers have been reported with an incidence of 0.7–2.4%, skin metastasis of glottic carcinoma is extremely rare. Case report: A 69-year-old male patient was admitted to the emergency department with hemoptysis, dyspnea, weakness in lower extremities and difficulty in swallowing. There were subcutaneous lesions with a diameter of 2–5 cm in the scalp, posterior chest wall, nose and abdomen. In addition, there was an ulcerating, painful mass on the right lateral part of the tongue. The biopsy of lesions on tongue and skin revealed a glottic squamous cell carcinoma with cutaneous metastasis. Management and outcome: The patient was treated with cisplatin 50 mg/m2 on day 1, cetuximab 500 mg/m2 on day 1 and 5-fluorouracil 1000 mg/m2 daily on days 1 and 2, repeated every two weeks. After the first cycle of chemotherapy, the lesions on the skin regressed and dysphagia improved. Discussion: There are limited data about the incidence, diagnostic measures and treatment modalities of glottic cancer with cutaneous metastasis. Our case could provide an important experience to literature by its atypical presentation and treatment-sensitive nature.